



BC Centre for Disease Control
An agency of the Provincial Health Services Authority

Date: April 22, 2015

Administrative Circular: 2015:04

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program, Section VII – Biological Products**

Section VII - Biological Products

For all of the immune globulin products, the following *general* updates have been made:

Product pages re-formatted and content re-organized to be consistent across all of the immune globulin products.

Precaution related to the administration of immune globulin products to individuals with bleeding disorders revised to reflect current recommendations.

Precaution related to the administration of immune globulin products to individuals with IgA deficiency updated to include the recommendation that these products should be administered in an emergency room setting due to the increased risk of anaphylaxis.

Special consideration added related to documentation after administration of immune globulin products.

Adverse events updated.

New adverse event added: A potential increased risk of thrombosis (blood clots) has been observed within 24 hours of receipt of immune globulin products, especially when given in large doses (i.e. more than 10 mL). Additional risk factors include: age 45 years and older, history of thrombosis or those with risk factors for thrombosis (e.g., obesity, high blood pressure, diabetes, prolonged periods of immobilization, use of estrogens, a history of heart disease, blood clotting disorders, indwelling central vascular catheters, or diseases that thicken the blood).

Product specific updates include:

Hepatitis B Immune Globulin (HBIG)

Product names and suppliers updated. Product components added.

Special consideration added related to ordering HBIG.

Please remove page numbers: 11 - 12

Dated: April 2010

Please add new page numbers: 11, 12, 12a

Dated: April 2015

Immune Globulin (Ig)

Product supplier name updated. Product components added.

Immune Globulin Preparations (HBIG, Ig, TIg, VarIg, RabIg):

- Page reformatted but content unchanged

Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:

- Table order reformatted to list standard immune globulin products, followed by specific immune globulin products and blood products.
- Cytomegalovirus immune globulin (CMVIG) added.
- Intravenous immune globulin (IVIg) and Rh immune globulin (RhIg) doses and timing intervals for live vaccine administration updated.
- Receipt of packed red blood cells and timing interval for live vaccine administration updated.
- Botulism immune globulin (BabyBIG®) dose updated.
- Footnotes updated to reflect 3 month interval between receipt of RhIg and MMR and Varicella vaccines.

Please remove page numbers: 26 - 30

Dated: November 2010, April 2010 and January 2012

Please add new page numbers: 26, 27, 27a, 28, 29 & 30

Dated: April 2015

Rabies Immune Globulin (Rablg)

Product components updated.

Precaution added regarding giving Rablg with caution (i.e. in an emergency room setting) if the client has a history of anaphylactic reaction following receipt of any immune globulin product or history of anaphylactic reaction to any component of HyperRAB® S/D or IMOGRAM® (assess risks versus benefits).

Please remove page numbers: 53 - 54
Dated: May 2014

Please add new page numbers: 53, 54, 54a
Dated: April 2015

Tetanus Immune Globulin (Tlg)

Product components added.

Precaution added regarding giving Tlg with caution (i.e. in an emergency room setting) if the client has a history of anaphylactic reaction following receipt of any immune globulin product or history of anaphylactic reaction to any component of HYPERTET® S/D (assess risks versus benefits).

Tetanus Prophylaxis in Wound Management

- Table re-formatted and product specific information removed from footnotes.

Please remove page numbers: 67 - 69
Dated: April 2010 & January 2009

Please add new page numbers: 67 - 69
Dated: April 2015

Varicella Zoster Immune Globulin (Varlg)

Special consideration added related to ordering Varlg.

Please remove page numbers: 76 - 77
Dated: April 2010

Please add new page numbers: 76 - 77
Dated: April 2015

Please also remove the Table of Contents for Section VII – Biologicals Products dated March 2015 (2 pages) and replace with the enclosed updated Table of Contents section dated April 2015 (3 pages).

BC Centre for Disease Control

An agency of the Provincial Health Services Authority

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at Christine.halpert@bccdc.ca.

Sincerely,



Monika Naus, MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Dr. Evan Adams
Deputy Provincial Health Officer for Aboriginal Health

Craig Thompson
Director, CD Prevention – Immunization

Warren O'Briain
Executive Director,
Communicable Disease and Addiction Prevention